Cardiology

Data from 4 of the most impactful trials presented at the American Heart Association Scientific Sessions 2025.

Lau discusses the use of virtual shared medical appointments for increasing access to cardiovascular care in a traditionally underserved population.

Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

Lau discusses the importance of developing and applying technology to predict potential adverse cardiovascular outcomes in pregnant patients.

Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.

Although the initial MACE composite outcome was not statistically significant, investigators saw follow-up MI risk reduced by >50%.

The SGLT2 inhibitor also displayed its efficacy in reducing left ventricular myocardial fibrosis and volume, as well as improving diastolic filling dynamics.

McLaughlin discussed the previous ZENITH, PULSAR, and STELLAR trials, and how this pooled cohort analysis emphasizes sotatercept’s impressive efficacy.

Data from the DECAF study suggests caffeine may have a slightly beneficial effect on AF recurrence, although investigators urge caution in interpretation.

Navar discusses the groundbreaking results of this phase 3 trial, as well as the implications of an oral PCSK9 inhibitor for treatment adherence and persistence.

REGN7508 and REGN9933 displayed their efficacy in preventing deep venous thromboembolism in patients undergoing knee replacement surgery in 2 phase 2 clinical trials.

This first-in-human phase 1 trial resulted in a groundbreaking reduction in both LDL cholesterol and triglycerides for the first time in history.

The investigative RNA-targeted antisense oligonucleotide achieved a reduction in fasting triglyceride of >72% in 6 months and sustained it through 12.

Branch explains the evolving understanding of the role genetic variants play in driving hepatic steatosis and associated cardiovascular risk or protection.

Adding evolocumab to existing lipid-lowering therapies significantly reduced first MACE risk, highlighting its efficacy in reducing cardiovascular mortality.

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Khush discusses the promising results of the recent SHORE study, highlighting the new biomarker’s capacity for reducing surgical procedures.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

Exposure to nonoptimal temperatures have shown an association with deaths among patients with heart failure.

Recent research has highlighted the influence of minor beat-to-beat changes in blood pressure on the left side of the brain.

A recent European study has confirmed prior American data showing the predictive ability of this combination measurement in healthy patients.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Preeclampsia, gestational diabetes, preterm delivery, large for gestational age, and other hypertensive disorders of pregnancy are now risk factors.